Latest Blog Posts Tagged "Affitope"
September 07, 2016
Austrian biotech AFFiRiS reports a boost dose of its vaccine against key protein alpha-synuclein is safe and elicits antibodies. MJFF funded the trial.
November 04, 2014
Researchers shared updates on the current research in understanding Parkinson's and developing new drugs at the annual Parkinson's Disease Therapeutics Conference.
July 31, 2014
The Austrian biotech AFFiRiS AG announced positive results of its Phase I safety trial of a vaccine against alpha-synuclein, a treatment that could slow or stop Parkinson's disease .
April 29, 2014
Results from the first study on Parkinson's disease vaccine drug candidates are expected later this year.
Three Questions for a Researcher with Markus Mandler, PhD, Head of the Neurodegeneration Department at AFFiRiS AG
May 09, 2013
Markus Mandler's team at AFFiRiS AG is currently testing a vaccine called PD01, the first Parkinson's drug to target alpha-synuclein to make it to the clinic.